ORN and ORY Related Headlines
Go Back- ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
- ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
- ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
- ORYZON to Participate in Upcoming Events in May and June
- ORYZON receives US patent allowance for vafidemstat BPD treatment
- ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
- ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
- ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
- ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
- ORYZON to Participate in Upcoming Events in February and March
- Oryzon appoints Rolando Gutierrez-Esteinou as chief medical officer for CNS
- ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
- ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
- ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
- ORYZON to Participate in Upcoming Events in January
- ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
- ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
- ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
- ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025
- ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
- ORYZON to Participate in Upcoming Events in November
- ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
- ORYZON receives FDA feedback on phase III borderline personality disorder trial
- ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
- ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
- ORYZON to Participate in Upcoming Events in September and October
- ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study
- ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
- ORYZON Finalist at the 2025 European Lifestars Awards
- ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
ORN and ORY Related Press Releases
Go Back- ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
- ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
- ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
- ORYZON to Participate in Upcoming Events in May and June
- ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
- ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
- ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
- ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
- ORYZON to Participate in Upcoming Events in February and March
- ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
- ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
- ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
- ORYZON to Participate in Upcoming Events in January
- ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
- ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
- ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
- ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025
- ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
- ORYZON to Participate in Upcoming Events in November
- ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
- ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
- ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
- ORYZON to Participate in Upcoming Events in September and October
- ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study
- ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
- ORYZON Finalist at the 2025 European Lifestars Awards
- ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
